Agerafenib hydrochloride

N/A

Report date: 2026/05/14 20:00:28
NME

Base Information

Drug NameAgerafenib hydrochloride
Drug Alias NameagerafenibCEP-32496RXDX-105AC013773
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsTyrosine-protein kinase receptor RET inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1Tyrosine-protein kinase receptor RETSerine/threonine-protein kinase B-raf
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTevaDaiichi Sankyo Co LtdAmbit Biosciences Co +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesF. Hoffmann-La Roche LtdTeva Pharmaceutical Industries LtdCephalon
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A